Martin Müller

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Andreas Hochhaus, S G O'Brien, François Guilhot et al. · Leukemia · 2009 · 845 citations

Medicine, Hematology, Oncology +5

Carrageenan Is a Potent Inhibitor of Papillomavirus Infection

Christopher B. Buck, Cynthia D. Thompson, Jeffrey N. Roberts et al. · PLoS Pathogens · 2006 · 499 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C.P. Cross et al. · Blood · 2008 · 389 citations · Full text

Medicine, Biostatistics, Performance Measurement +9

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

Rengaswamy Sankaranarayanan, Priya R. Prabhu, Michael Pawlita et al. · The Lancet Oncology · 2015 · 248 citations · Full text

Veterinary Medicine, Immunology, Preventive Medicine +17

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Neha Shah, D.-W. Kim, Hagop M. Kantarjian et al. · Haematologica · 2010 · 243 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13